Search

Displaying results 3451 - 3460 of 8412 in total
  1. Drug

    Hydrocortisone butyrate

    go.drugbank.com/drugs/DB14540
    ApprovedVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  2. Drug

    Hydrocortisone probutate

    go.drugbank.com/drugs/DB14543
    ApprovedVet approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inducers
  3. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved by the F...

  4. Drug

    Girentuximab

    go.drugbank.com/drugs/DB05304
    Investigational

    Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).

  5. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond....

  6. Drug

    Linseed oil

    go.drugbank.com/drugs/DB11357
    Investigational

    It is an indirect additive used in food contact substances. … Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen in air due to a high content of di- and triunsaturated esters.

  7. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

  8. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates
  9. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  10. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).